Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.70 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | TSPO | P30536 | 1/20 | 0.64 |
| ▸ | BRD2 | P25440 | 7/20 | 0.62 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.62 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.62 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | BRD1 | O95696 | 1/20 | 0.61 |
| ▸ | CCL2 | P13500 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | EP300 | Q09472 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21349528 | 1.00 | BRD4 (0.70) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL9040027 | 0.91 | BRD4 (0.58) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL19986290 | 0.88 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL21392840 | 0.88 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL18463912 | 0.88 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL16976612 | 0.88 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL17059531 | 0.88 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL9041912 | 0.88 | BRD4 (0.60) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL23320742 | 0.87 | BRD4 (0.70) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL22861828 | 0.87 | BRD4 (0.67) | BRD4DNERADORA3TSPOBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-10-01 | — | — | US | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-4105220-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| EP-0692483-A1 | CELL ADHESION INHIBITOR AND THIENOTRIAZOLODIAZEPINE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | BRD4 1/4885DNER 2244/4885ADORA3 4839/4885 |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | BRD4 1/4885DNER 2244/4885ADORA3 4839/4885 |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | BRD4 1/4885DNER 2244/4885ADORA3 4839/4885 |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | BRD4 2/4885DNER 780/4885ADORA3 4629/4885 |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | BRD4 1/4885DNER 2244/4885ADORA3 4839/4885 |
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | BRD4 1/4885DNER 2244/4885ADORA3 4839/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | BRD4 2/4885DNER 690/4885ADORA3 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.